A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

This study is testing novel agents combined with radiation therapy in patients with non-small cell lung cancer (NSCLC) who are not suitable for surgery or standard combined chemoradiation. It uses a platform approach, meaning multiple treatment combinations can be tested under one master protocol. **You may be eligible if...** - You are 18 or older with confirmed non-small cell lung cancer (NSCLC) - Your cancer is stage IIB or III (locally advanced, but not yet widely spread) - You are not a suitable candidate for surgery or concurrent chemoradiation due to your tumor location or overall health - You are planned to receive radiation therapy at a curative dose (60 Gy) - If you received prior chemotherapy, the last dose was within 10 weeks of starting radiation **You may NOT be eligible if...** - You have widely metastatic (stage IV) disease - Your overall health is too poor for radical radiation therapy - You have significant uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.